Description
A potent, orally active, dual inhibitor of c-Kit and VEGFR-2 (KDR) with IC50 of 15nM and 9nM, respectively; also inhibits Lck, c-Raf, Flt1, and CSF-1R (IC50<100 nM); exhibits antitumor activity in mutant Kit-expressing HMC-1 xenograft model. Solid Tumors Phase 1 discontinued